醋酸格拉替雷治疗复发缓解型多发性硬化症的疗效、安全性和成本效益。
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
机构信息
Multiple Sclerosis Center, Department of Neurology The Ohio State University Medical Center 395 West 12th Avenue, 7th floor Columbus, OH 43210, USA.
出版信息
Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.
Abstract
The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.
摘要
目前多发性硬化症（MS）的治疗领域正在迅速发展。醋酸格拉替雷（GA）因其非免疫抑制作用机制以及优越的长期安全性和持续疗效数据而独具特色。在这篇综述中，我们讨论了 GA 的作用机制。然后，我们回顾了减少复发和减缓残疾的疗效数据以及长期安全性数据。最后，我们讨论了这种独特聚合物在 MS 治疗中的可能未来方向。
相似文献
1
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.醋酸格拉替雷治疗复发缓解型多发性硬化症的疗效、安全性和成本效益。
Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.
2
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.皮下注射醋酸格拉替雷二十年：标准剂量的当前作用以及新型高剂量低频醋酸格拉替雷在复发缓解型多发性硬化症治疗中的作用
Patient Prefer Adherence. 2014 Aug 21;8:1123-34. doi: 10.2147/PPA.S68698. eCollection 2014.
3
Glatiramer in the treatment of multiple sclerosis.醋酸格拉替雷治疗多发性硬化症
Int J Nanomedicine. 2006;1(3):283-9.
4
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.美国迟释型富马酸二甲酯治疗复发型多发性硬化症的成本效益
J Med Econ. 2016;19(4):432-42. doi: 10.3111/13696998.2015.1135805. Epub 2016 Jan 20.
5
Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.醋酸格拉替雷：复发缓解型多发性硬化症的长期安全性和疗效
Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175.2015.1040768. Epub 2015 Apr 30.
6
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
7
What is new in the treatment of multiple sclerosis?多发性硬化症治疗方面有哪些新进展？
Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002.
8
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.醋酸格拉替雷治疗复发缓解型多发性硬化。
Expert Rev Neurother. 2012 Apr;12(4):371-84. doi: 10.1586/ern.12.25.
9
Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.醋酸格拉替雷和那他珠单抗用于复发缓解型多发性硬化症的成本效益
Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.1007/BF03256144.
10
Therapy with glatiramer acetate for multiple sclerosis.醋酸格拉替雷治疗多发性硬化症
Cochrane Database Syst Rev. 2004(1):CD004678. doi: 10.1002/14651858.CD004678.
引用本文的文献
1
Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report.醋酸格拉替雷致药物性肝损伤并导致肝移植：一例报告
JGH Open. 2023 Jul 26;7(8):591-593. doi: 10.1002/jgh3.12938. eCollection 2023 Aug.
2
Amyloid Precursor Protein and Tau Peptides Linked Together Ameliorate Loss of Cognition in an Alzheimer's Disease Animal Model.淀粉样前体蛋白和tau肽联合可改善阿尔茨海默病动物模型中的认知功能丧失。
Int J Mol Sci. 2023 Aug 7;24(15):12527. doi: 10.3390/ijms241512527.
3
Neurodegeneration in multiple sclerosis.多发性硬化中的神经退行性变。
WIREs Mech Dis. 2023 Jan;15(1):e1583. doi: 10.1002/wsbm.1583. Epub 2022 Aug 10.
4
Macrophage reprogramming for therapy.巨噬细胞重编程治疗。
Immunology. 2021 Jun;163(2):128-144. doi: 10.1111/imm.13300. Epub 2021 Jan 25.
5
Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.醋酸格拉替雷的即时反应：过敏诊断与脱敏方案
Neurol Clin Pract. 2020 Apr;10(2):170-177. doi: 10.1212/CPJ.0000000000000714.
6
Managing Risks with Immune Therapies in Multiple Sclerosis.多发性硬化症的免疫治疗风险管理。
Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8.
7
The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria.免疫调节药物醋酸格拉替雷也是一种有效的抗菌药物，能够杀死革兰氏阴性菌。
Sci Rep. 2017 Nov 15;7(1):15653. doi: 10.1038/s41598-017-15969-3.
8
Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.免疫调节在肌萎缩侧索硬化症治疗中的应用：临床试验综述
Front Neurol. 2017 Sep 25;8:486. doi: 10.3389/fneur.2017.00486. eCollection 2017.
9
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.多发性硬化症的口服疾病修饰疗法。
Curr Neurol Neurosci Rep. 2016 Apr;16(4):38. doi: 10.1007/s11910-016-0639-4.
10
Disease-modifying therapies and infectious risks in multiple sclerosis.多发性硬化症的疾病修正治疗和感染风险。
Nat Rev Neurol. 2016 Apr;12(4):217-33. doi: 10.1038/nrneurol.2016.21. Epub 2016 Mar 4.
本文引用的文献
1
The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis.T1 低信号病灶强度变化对多发性硬化症临床相关性的影响。
Mult Scler. 2011 Aug;17(8):949-57. doi: 10.1177/1352458511402113. Epub 2011 Apr 18.
2
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.多发性硬化症治疗决策的批判性评价——旧与新。
Nat Rev Neurol. 2011 May;7(5):255-62. doi: 10.1038/nrneurol.2011.41. Epub 2011 Apr 5.
3
Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.神经炎症和神经保护：多发性硬化治疗中（未来）神经营养因子相关策略的最新进展。
Curr Med Chem. 2011;18(12):1775-84. doi: 10.2174/092986711795496881.
4
Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.多发性硬化症用醋酸格拉替雷的 III 期剂量比较研究。
Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.
5
The potential role of B cell-targeted therapies in multiple sclerosis.B 细胞靶向治疗在多发性硬化中的潜在作用。
Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000.
6
Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation.比较美国员工多发性硬化症的治疗前后成本和缺勤情况。
Curr Med Res Opin. 2011 Jan;27(1):179-88. doi: 10.1185/03007995.2010.540006. Epub 2010 Dec 7.
7
Interferon-β-1b: a review of its use in multiple sclerosis.干扰素-β-1b：在多发性硬化症中的应用综述。
CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000.
8
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.脑源性神经营养因子在神经保护性自身免疫中的功能作用：多发性硬化模型中的治疗意义。
Brain. 2010 Aug;133(Pt 8):2248-63. doi: 10.1093/brain/awq179.
9
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.11 例多发性硬化症孕妇长期使用醋酸格拉替雷：回顾性多中心病例系列。
CNS Drugs. 2010 Nov;24(11):969-76. doi: 10.2165/11538960-000000000-00000.
10
Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.醋酸格拉替雷对既往接受干扰素-β治疗和初治的复发缓解型多发性硬化症患者痉挛的影响：一项前瞻性、非随机、开放标签、非对照、观察性研究。
Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005.
Zotero 插件